Medlive Technology Co., Ltd.
Medlive Technology Co., Ltd. Fundamental Analysis
Medlive Technology Co., Ltd. (2192.HK) shows moderate financial fundamentals with a PE ratio of 16.73, profit margin of 52.05%, and ROE of 6.83%. The company generates $0.6B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 65.1/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 2192.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak2192.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate2192.HK shows balanced valuation metrics.
Growth Score
Moderate2192.HK shows steady but slowing expansion.
Financial Health Score
Excellent2192.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate2192.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 2192.HK Expensive or Cheap?
P/E Ratio
2192.HK trades at 16.73 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 2192.HK's PEG of 8.39 indicates potential overvaluation.
Price to Book
The market values Medlive Technology Co., Ltd. at 1.14 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 45.74 times EBITDA. This signals the market has high growth expectations.
How Well Does 2192.HK Make Money?
Net Profit Margin
For every $100 in sales, Medlive Technology Co., Ltd. keeps $52.05 as profit after all expenses.
Operating Margin
Core operations generate 19.75 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.83 in profit for every $100 of shareholder equity.
ROA
Medlive Technology Co., Ltd. generates $6.42 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medlive Technology Co., Ltd. produces operating cash flow of $155.81M, showing steady but balanced cash generation.
Free Cash Flow
Medlive Technology Co., Ltd. generates strong free cash flow of $134.66M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.18 in free cash annually.
FCF Yield
2192.HK converts 2.39% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
16.73
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
8.39
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.14
vs 25 benchmark
P/S Ratio
Price to sales ratio
8.77
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.002
vs 25 benchmark
Current Ratio
Current assets to current liabilities
19.09
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 2192.HK Stacks Against Its Sector Peers
| Metric | 2192.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 16.73 | 28.45 | Better (Cheaper) |
| ROE | 6.83% | 763.00% | Weak |
| Net Margin | 52.05% | -45266.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 19.09 | 2795.60 | Strong Liquidity |
| ROA | 6.42% | -16586.00% (disorted) | Weak |
2192.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medlive Technology Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation